Xencor Shares Rise 33% After Early-Stage Kidney Cancer Trial Data
Xencor said its treatment for certain forms of kidney cancer showed “impressive antitumor activity” in a recent early-stage trial. Shares rose 33% to $33.56 in premarket trading Monday.